|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||2.50 / 13.40|
Here are Friday's top research calls, including an upgrade for Ford and downgrades for Eaton, Altria and Ralph Lauren.
Here are Monday's top research calls, including downgrades for Air Products and Colgate-Palmolive, and upgrades for Disney and Noble.
Jim Cramer thinks Take-Two Interactive and Activision Blizzard have winning potential.
The idea of buying American and hiring American is good news for defense, ag and energy stocks, says Jim Cramer.
The Loxo phase II 'basket' study of larotrectinib is expected to complete patient enrollment in early 2017 and report results in the second half of the year.
Alaska Air is 'among the best,' says Jim Cramer; he also likes Southwest.
How did these technology stocks suddenly get their groove back? asks Jim Cramer.
The market isn't buying that Trump is bad for business
Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.
Following the success of Array BioPharma's (ARRY) melanoma treatment in a clinical trial announced yesterday, JPMorgan increased its price target on the stock.
Debate switches futures into positive territory after down day on Wall Street.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Array BioPharma Inc. , where a total volume of 19,126 contracts has been traded thus far today, a contract volume which is representative of approximately 1.9 million underlying shares (given that every 1 contract represents 100 underlying shares).
Here's a technical look at how to trade some of the most active stocks on the market right now.
I'm even staying away from the appealing stocks.
Array BioPharma (ARRY) announced on Monday that the company's treatment for metastatic melanoma met its primary endpoint in a late-stage clinical trial.
These low-dollar biotech stocks are making big moves Monday -- in opposite directions.
Insiders at these companies have been scooping up shares of their own stock lately.
Investors in Array BioPharma Inc. saw new options become available this week, for the November 18th expiration.
Jefferies upped its price target on Array BioPharma (ARRY) to $7 earlier today.
The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 2,190,797 share decrease in total short interest for Array BioPharma Inc. , to 14,071,789, a decrease of 13.47% since 07/29/2016.
Investors in Array BioPharma Inc. saw new options begin trading today, for the October 21st expiration.
Array BioPharma (ARRY) stock was tumbling in late-afternoon trading after the company's cancer drug trial failed to meet its primary endpoint.
Trade-Ideas LLC identified Array BioPharma (ARRY) as a pre-market mover with heavy volume candidate
Biotech stocks remain pressured following the recent Brexit vote, which will make investing in these already highly volatile stocks even trickier. But there are opportunities too.